Anavex Drug Delivers Positive Phase 2 Schizophrenia Results
ANAVEX3-71 met its primary endpoint in a placebo-controlled Phase 2 study in adults with schizophrenia on stable antipsychotic therapy,...
eClinical Tech News
Promising VQ-101 Trial Data Offers New Hope for Parkinson’s
VQ-101 delivered more than 70% activation of lysosomal glucocerebrosidase in GBA-Parkinson’s patients after 28 days of once-daily dosing, exceeding...
ALX Oncology Links CD47 to HER2+ Gastric Cancer Outcomes
ALX Oncology will present updated Phase 2 data from ASPEN-06, indicating that tumor CD47 overexpression may predict response to...
Vielight Summit: Groundbreaking New Tech For Meditation
No new clinical efficacy endpoints were disclosed. Vielight introduced a meditation-specific protocol within its Neuro Pro photobiomodulation device and...
Camp4’s Pioneering SYNGAP-1 Drug Enters Toxicology Studies
CAMP4 Therapeutics has begun GLP toxicology studies for CMP-SYNGAP-01, an intrathecally delivered antisense oligonucleotide designed to upregulate SYNGAP1 expression...
New AML Clinical Trial Targets Dual NPM1 & FLT3 Mutations
Kura Oncology and Kyowa Kirin have dosed the first patient in a new cohort of the Phase 1b KOMET-007...
Comphya Implants First CaverStim Device in U.S. Pilot Study
A 20-patient, single-site U.S. pilot has begun enrolling at Johns Hopkins under an FDA IDE to evaluate the safety...
Nuwellis: 92% Survival in Kids with Kidney Injury, Failure
Topline: In a multicenter registry of 91 critically ill pediatric patients treated with the Aquadex ultrafiltration system, 92% survived...
Silexion Data Shows Powerful 99.7% KRAS Cancer Inhibition
Silexion reported new preclinical data showing its RNAi candidate SIL204 inhibited proliferation by 83.5% to 99.7% across 11 human...
Vivex RESTORE Trial: A New Hope for Degenerative Disc Disease
Vivex Biologics has dosed the first patient in Restore, a randomized, double‑blind, sham‑controlled U.S. trial of VIA Disc NP...